Nightingale Health Gets Green Light From Singapore's Health Authority For New Healthcare Use

Nightingale Health Plc, a leader in disease risk detection and preventative healthcare, has secured further regulatory approval from Singapore’s Health Sciences Authority (HSA). The HSA is the national authority overseeing medical devices, therapeutics, and various healthcare products in Singapore.

Earlier this year, Nightingale Health announced its initial approval for the analysis of eight widely used clinical biomarkers, including total cholesterol, HDL and LDL cholesterol, triglycerides, apolipoprotein A1, apolipoprotein B, glucose, and creatinine. The newly obtained regulatory approval now extends to the analysis of various fatty acids, encompassing total fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, saturated fatty acids, omega-3, and omega-6 fatty acids.

Since late 2023, Nightingale Health has collaborated with Innoquest Diagnostics, a top clinical diagnostics service provider in Singapore, to facilitate access to its advanced blood analysis technology across Southeast Asia. This latest regulatory milestone marks a significant advancement toward the launch of Nightingale Health’s comprehensive blood testing services in the region.

The approval was granted following a thorough evaluation to ensure that Nightingale Health’s product meets the stringent safety and performance standards required for medical devices. With this HSA endorsement, Nightingale Health’s offering has been validated for its high standards of quality, safety, and effectiveness. Meeting these rigorous global regulatory benchmarks underscores the relevance of Nightingale Health’s technology in routine blood testing, equating it with the precision and reliability of established gold-standard tests.

Additionally, unlike existing methods, Nightingale Health’s technology elevates standard blood testing by providing an extensive array of familiar gold-standard biomarkers. More significantly, it delivers cutting-edge risk assessments for a range of chronic diseases from each test sample, paving the way for the development of more preventive and sustainable healthcare systems worldwide.

Teemu Suna, CEO and Founder of Nightingale Health, said “Nightingale Health’s blood analysis technology demonstrates again its capabilities to become the new improved standard in routine blood testing for chronic diseases. By replacing the current methods of clinical chemistry, Nightingale Health’s blood test can offer groundbreaking value in building more preventative and sustainable healtcare.”

Suna further added, “Our technology not only replaces directly many of the common blood values, but importantly offers additionally, for the first time in the diagnostic industry, a possibility to detect comprehensively the risk for developing chronic diseases. These capabilities are enabled by the unique combination of Nightingale Health’s proprietary blood analysis technology and pioneering population data driven approach.”

Suna concluded by saying, “Nightingale Health’s technology is already used in nationwide primary healthcare in Finland covering approximately 30% of Finland’s working population. In addition to Singapore, we are also making rapid progress in the United States and in the United Kingdom in adopting our technology in healthcare. We are truly excited to bring the advantages of modern blood testing technology available around the world, and the additional regulatory approval in Singapore continues to demonstrate the high quality and performance of our unique technology.”